Barinthus Biotherapeutics Collaborates With Coalition For Epidemic Preparedness Innovations And University Of Oxford, To Fast-track VTP-500 Vaccine Development For The Prevention Of Middle East Respiratory Syndrome, CEPI To Invest Funding Of Up To $34M
Portfolio Pulse from Benzinga Newsdesk
Barinthus Biotherapeutics is collaborating with the Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Oxford to accelerate the development of the VTP-500 vaccine, aimed at preventing Middle East Respiratory Syndrome (MERS). CEPI will invest up to $34 million in funding for this initiative.
December 21, 2023 | 12:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barinthus Biotherapeutics is set to receive up to $34 million from CEPI for the development of the VTP-500 vaccine against MERS, in collaboration with the University of Oxford.
The collaboration and significant funding from CEPI for Barinthus Biotherapeutics are likely to have a positive impact on the company's financials and its position in the biotech industry. The partnership with a prestigious institution like the University of Oxford further adds credibility to the project, potentially increasing investor confidence in the company's future prospects.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100